Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Combination targeted therapy with Janus kinase inhibition plus biologic agents in refractory JIA: an international multi-centre case series.

Created on 12 Nov 2026

Authors

Marcus Sim, Joshua Bennett, Barrak Almoosawi, Rawan Almubarak, Octavio Aragon Cuevas, Samantha Cooray, Jessica Fisher, Orla G Killeen, Jayne MacMahon, Joanne May, Irfan Nengroo, Nandita Pai, Lucy Paterson-Brown, Elizabeth Twynam-Perkins, Mark Wood

Published in

Rheumatology (Oxford, England). Nov 12, 2026. Epub Nov 12, 2026.

Abstract

To describe multi-centre real-world experience of combination targeted therapy (CTT) using a Janus kinase inhibitor (JAKi) and biologic in juvenile idiopathic arthritis (JIA).
Paediatric rheumatology centres across the United Kingdom and Republic of Ireland with experience of JAKi-biologic CTT use in JIA were identified. Written patient consent and local approval was obtained.Data on patient characteristics, treatment history, adverse events, and disease activity were collected by retrospective review of medical records. Paired data were analysed using Wilcoxon signed-rank test.
13 patients with JIA were identified (11 Still's disease/systemic; 1 psoriatic; 1 extended oligoarticular) across nine centres. Historical joint damage (39%) and glucocorticoid toxicity (77%) were common.Median 5 conventional/biologic/targeted synthetic DMARDs (IQR 4-7) were used over a median 66 months (IQR 36-133) before CTT initiation at median age 12 years (IQR 9-14). Tofacitinib-tocilizumab was the most frequent combination.CTT was used briefly as bridging therapy in 2/13, with 11/13 remaining on CTT for ≥12 months, permitting paired analysis at 12 months. A significant reduction in 12-month intravenous methylprednisolone exposure (median 109mg/kg vs. 0mg/kg; p=0.013) and active joint count (median 5 vs. 2 joints; p=0.009) was seen. At last follow-up (median 21.5 months), 6/10 still on CTT had inactive disease, with 8/10 off systemic steroids.No serious infections occurred. Two non-infectious serious adverse events were reported; hip avascular necrosis and pulmonary alveolar proteinosis.
JAKi-biologic CTT may have a role in improving disease control in refractory JIA, enabling some reduction in glucocorticoids, with no serious infections reported.

PMID:
43016356
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 7
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement